stockrowSotera Health Company
SHC Healthcare Diagnostics & Research
Sotera Health Company’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 5.74% from fiscal 2024.
- Revenue
- +4.36%
- EPS
- +20.1%
- Free cash flow
- +65.0%
- Total debt
- +0.14%
Quarter to September 2026, against a year earlier
Follow SHC
Alert me
Sotera Health Company (SHC) EV/Sales
As of 5 November 2026, Sotera Health Company (SHC) trades at a EV/Sales of 5.2×. Over the past ten years it has ranged from 3.3× (November 2022) to 11.8× (December 2020); the current reading is higher than 21% of that period. That is in line with the Diagnostics & Research industry median of 5.2× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.9× | 10.41% |
| FY2024 | 5.4× | (15.34%) |
| FY2023 | 6.3× | 61.62% |
| FY2022 | 3.9× | (55.77%) |
| FY2021 | 8.9× | (16.80%) |
| FY2020 | 10.7× | (2.55%) |
| FY2019 | 10.9× | 0.00% |
| FY2018 | 10.9× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 5.8× | 1.31% |
| Jun 2026 | 5.7× | 13.19% |
| Mar 2026 | 5.0× | (14.86%) |
| Dec 2025 | 5.9× | 6.46% |
| 24 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VCYT Veracyte, Inc. compare | 2.5× |
| RDNT RadNet, Inc. compare | 3.0× |
| NEO NeoGenomics, Inc. compare | 3.3× |
| SHC Sotera Health Company | 5.2× |
| QGEN QIAGEN N.V. compare | 5.4× |
| CDNA CareDx, Inc. compare | 7.6× |
| BLLN BillionToOne, Inc. compare | 11.0× |
| ADPT Adaptive Biotechnologies Corporation compare | 14.6× |
| GRAL GRAIL, Inc. compare | 29.8× |
| Diagnostics & Research industry median | 5.2× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on SHC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement